SUMO-specific protease 1 exacerbates acute myeloid leukemia by enhancing beclin 1-dependent autophagy through polypyrimidine tract-binding protein 1 deSUMOylation
Journal of Leukocyte Biology · 2024
DOI: 10.1093/jleuko/qiae143 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Leukocyte Biology, 2024. Verfasst von Lina Xing und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The Second Hospital of Hebei Medical University, Hebei Key Laboratory of Hematology, No. 215, West Heping Road, Shijiazhuan…. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Polypyrimidine Tract-Binding Protein, Autophagy, Beclin-1. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: Hebei Medical Science Research Project, Natural Science Foundation of Hebei.
Abstract (Originalsprache)
Genetic association between SUMO-specific protease 1 (SENP1) and acute myeloid leukemia (AML) has been validated. However, the mechanism by which SENP1 affects AML proliferation, apoptosis, and autophagy remains unknown. The levels of SENP1 and polypyrimidine tract-binding protein 1 (PTBP1) were measured in patients with AML, AML cell lines, and xenograft tissues. The effects of SENP1 on AML proliferation, apoptosis, and beclin 1 (BECN1)-dependent autophagy were assessed through in vitro and in vivo loss- or gain-of-function experiments. SUMOylation analysis using immunoprecipitation (IP), RNA pull-down, RNA IP (RIP), and RNA stability assays were used to explore the molecular mechanism of SENP1 in AML development. The SENP1 level was elevated in AML samples. Silencing SENP1 impeded the development of AML, as evidenced by the inhibition of proliferation and promotion of G1-phase arrest and apoptosis resulting from SENP1 depletion in AML cells. Moreover, silencing of SENP1 restrained BECN1-depentent autophagy in AML cells. In addition, the overexpression of BECN1 or PTBP1 partially neutralized the effect of SENP1 knockdown on AML cell behavior. Mechanistically, SENP1 mediated PTBP1 deSUMOylation, which then directly interacted with BECN1 mRNA and enhanced its stability. In vivo experiments further confirmed the repressive effects of SENP1 suppression on AML development. Collectively, the SENP1/PTBP1/BECN1 signaling axis has been identified as a significant therapeutic target for enhancing AML treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, The Second Hospital of Hebei Medical University, Hebei Key Laboratory of Hematology, No. 215, West Heping Road, Shijiazhuang 050000, Hebei Province, China.
Förderung
- Hebei Medical Science Research Project
- Natural Science Foundation of Hebei
Zitieren
APA
Xing, L., Guo, X., Zhang, X., Wang, Y., & Ren, J. (2024). SUMO-specific protease 1 exacerbates acute myeloid leukemia by enhancing beclin 1-dependent autophagy through polypyrimidine tract-binding protein 1 deSUMOylation. Journal of Leukocyte Biology. https://doi.org/10.1093/jleuko/qiae143
Vancouver
Xing L, Guo X, Zhang X, Wang Y, Ren J. SUMO-specific protease 1 exacerbates acute myeloid leukemia by enhancing beclin 1-dependent autophagy through polypyrimidine tract-binding protein 1 deSUMOylation. Journal of Leukocyte Biology. 2024. doi:10.1093/jleuko/qiae143
BibTeX
@article{Xing2024,
author = {Xing, Lina and Guo, Xuefei and Zhang, Xiaolei and Wang, Ying and Ren, Jinhai},
title = {SUMO-specific protease 1 exacerbates acute myeloid leukemia by enhancing beclin 1-dependent autophagy through polypyrimidine tract-binding protein 1 deSUMOylation},
journal = {Journal of Leukocyte Biology},
year = {2024},
doi = {10.1093/jleuko/qiae143}
}
EUVIMED